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The development of a system of plastic bags
connected by integral tubing for the collection,
processing and storage of blood has made it possible for selective transfusion of appropriate blood
components. It is now possible to select the blood
component that will correct a patient's physiologic
deficiency. This has resulted in better patient care
and in better utilization of blood since a single
unit of blood can be used to supply erythrocytes for
an anemic patient, platelets for a patient with
thrombocytopenia and factor VIII concentrate for
a patient with hemophilia.
In order to utilize blood and its components
optimally, there must be a close working arrangement between the blood bank personnel and the
clinical staff. At the time when blood is obtained
from a donor, a decision should be made concerning how the blood will be used. Several of
the components can be prepared only from fresh
blood. The equipment, supplies and personnel time
should be used to produce the maximum benefit
to the recipients of the blood. Although each unit
of blood could be separated into several useful components, it is a wasteful procedure if the components are not used. Each institution must determine its need for blood and blood components .
Those responsible for the operation of the blood
bank should not make unilateral decisions about
the preparation of blood components and the
clinical staff should not make unilateral decisions
about the use of blood components.
Packed Red Blood Cells. When blood is collected in the proper closed bag system, it is possible
to remove much of the plasma after sedimentation
or centrifugation without opening the container.
The resulting packed red blood cells remain viable
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for transfusion purposes for 21 days when stored
under standard conditions. The obvious advantage
of transfusing packed red blood cells is that the
circulating erythrocyte mass of the recipient can
be increased without increasing the circulating
plasma volume. This minimizes the possibility of
circulatory overload. It has been estimated that up
to 80 percent of the transfusions should be in the
form of packed red blood cells (2).
Along with the plasma, most of the sodium
added in the anticoagulant solution is removed. This
can be an important factor when transfusions are
necessary in patients requiring limited sodium intake. In addition to the excessive amounts of electrolytes and citric acid, the plasma contains antibodies. One of the dangers in the universal donor
concept is that the plasma of group O individuals
contains antibodies against group A and group B
cells. These antibodies are removed along with
the plasma. Although type specific compatible
erythrocytes are the treatment of choice, in an
emergency situation when such blood is not available, group O packed red blood cells are an acceptable form of therapy.
Factor VIII Concentrates. The treatment of
hemophilia with plasma rather than whole blood
was an early form of component therapy. It was
found that plasma contains the material lacking in
hemophilia and except for the occasional patient
with anemia, whole blood is seldom needed for
the treatment of hemophilia. Although the antihemophilic factor in plasma is relatively labile, it
can be maintained in plasma stored below -18 °C.
Until relatively recently, plasma removed from
whole blood within a few hours of collection and
then promptly frozen was the only available source
of factor VIII for human use. Because of the relatively small amount of antihemophilic activity in
plasma, large amounts of fluid had to be infused
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to significantly increase the circulating level in the
patient. In addition, the infused activity was retained in the circulation for only a short period
of time (4). Thus, therapy was restricted to the
amount of fluid that could be infused without causing overload.
In 1965, Pool and her associates (5) reported
that when frozen plasma was thawed slowly, a
poorly soluble, gelatinous precipitate was formed.
This material, called cryoprecipitate, was found to
contain a considerable amount of the antihemophilic activity of plasma. Thus, it became possible
to concentrate and collect factor VIII of plasma
in a closed bag system. The resulting material contains, on the average, about half of the antihemophilic activity of the original plasma and in a
relatively small volume.
Although the treated plasma can be returned
to the cellular component and used as whole blood,
most have found it better to utilize the plasma for
other purposes. The residual plasma can be used
for all conditions where plasma is indicated other
than for the treatment of hemophilia.
Platelet Concentrates. Fresh whole blood contains viable platelets which will function when
transfused. When platelets are needed to control
bleeding in a patient with thrombocytopenia, however, a large amount of blood must be infused to
increase the platelet level in the circulation. Platelets
can be separated from whole blood and transfused
in a relatively small volume.
Platelets have a specific gravity of 1.040 while
the specific gravity of erythrocytes is about 1.095
(3). Since platelets are lighter than erythrocytes,
the red blood cells can be sedimented by low speed
centrifugation while the platelets remain suspended
in plasma. In this way platelets can be separated
from whole blood in a closed bag system. Platelets,
however, have a very short shelf life and to be
effective must be infused promptly after collection.
Although platelets lose viability rapidly, approximately half of the recovered platelets are still effective after 72 hours of storage. Most workers, though,
feel that platelets should be used within the first
48 hours after collection. Although there is some
evidence that room temperature storage has some
advantages, it is felt that best results are obtained
when platelets are stored at 4 °C. Additional studies
of storage are necessary to determine optimal
conditions ( 1) .
Platelets can be given along with the plasma

as platelet rich plasma. It is usually necessary,
however, to give the platelets recovered from six
units of blood to achieve the desired effects and it
is normally not desirable to give this amount of
fluid. The usual practice is to concentrate the
platelets by centrifugation and remove all but approximately 30 ml of plasma. Following centrifugation, it may be difficult to resuspend the platelets.
Gentle agitation after storage for about one hour
has been found to result in a satisfactory product.
It is generally recommended that platelets be infused through a filter to remove any large
aggregates.
Plasmapheresis. One of the limitations of obtaining blood is that approximately six-to-eight
weeks are required for the regeneration of erythrocytes. For this reason, the interval between individual donations of blood should be at least eight
weeks. The regeneration of the fluid volume and
plasma proteins is more rapid. With a series of
bags connected by integral tubing, it is possible to
withdraw blood from a donor, separate the erythrocytes from the platelet rich plasma and return
the erythrocytes to the donor. This process, called
plasmapheresis, can be repeated at frequent intervals
without danger to the donor.
This technique has several advantages when
the needs for platelets and plasma are great. A
relatively small number of donors can supply considerable amounts of platelets and plasma. There
is increasing evidence that when platelets are given
over a prolonged period, antibodies to platelets
develop in the multitransfused patient. These antibodies appear to be directed against the histocompatibility antigens of the HL-A system. Those
institutions which use platelet transfusions on a
long-term basis have found that best platelet survival occurs when there is an HL-A compatibility
between donor and recipient. It is generally felt
that if a series of platelet transfusions are required,
it is best to obtain platelets by plasmapheresis from
a few histocompatible donors rather than utilizing
platelets from a number of random blood donors
(7).

Frozen Red Blood Cells. With currently available techniques, erythrocytes retain sufficient viability for transfusion purposes for only 21 days.
For this reason blood supplies must be continuous
and the blood bank must be able to predict its
needs so that sufficient blood will be available and
yet there will not be wastage due to excessive
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amounts of erythrocytes lost by out-date. An obvious solution would be to develop a method of
preservation of blood for longer periods.
A number of chemical additives have been
used in an attempt to prolong the viability of
erythrocytes. The most promising has been adenine
(6). With the addition of adenine at the time of
collection, there is evidence that erythrocytes remain viable up to 40 days under the usual storage
conditions. At the present time, however, there is
not sufficient evidence to be certain of the safety
of this material for human use .
Other workers have demonstrated that erythrocytes suspended in cryoprotective solutions retain
viability almost indefinitely when stored at low
temperatures. Before the erythrocytes can be infused , the cryoprotective materials must be removed.
The supplies and equipment necessary for preparation, storage and washing make this technique rather
expensive. Although the techniques are practical,
the cost for a unit of such blood is almost prohibitive for routine use. If methods can be developed to decrease the cost, there are many advantages to such a technique.
Leukocyte-Poor Blood. There are many known
antigens associated with erythrocytes, but most of
these are only occasionally of clinical significance.
For practical purposes, it is only necessary to
routinely test for ABO and Rh antigens. In a
similar way there are a number of antigens associated with leukocytes, but these are usually of
little clinical significance. In multitransfused patients, however, the leukocytes may cause reactions.
To prevent these reactions it may be necessary to
give leukocyte-poor blood. Recently it has been
recognized that leukocyte antigens may have an
adverse effect on organ transplantation. It has been
suggested that patients with chronic renal disease
who may be candidates for renal transplantation
should be given only leukocyte-poor blood.
The specific gravity of granulocytes is 1.0871.092 and the specific gravity of lymphocytes is
1.070 ( 3). Thus differenti al centrifugation to prepare
leukocyte-poor erythrocytes is rather difficult. There
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are techniques by which most of the leukocytes can
be separated from erythrocytes but these techniques
are tedious and time consuming. In order to remove
the leukocytes and their antigens it is necessary
that fresh blood be used. In those institutions that
have a frozen blood program, it has been found
that this preparation is an excellent source of
leukocyte-poor erythrocytes.
Summary. At the present time there are a
number of blood components that are more suitable
for transfusion purposes than is whole blood. In
order to make maximum use of blood, it is necessary that there be close cooperation between the
blood bank personnel and those responsible for
patient care.
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